Stephanie Herron was named chief development officer of Stand Up To Cancer. In this newly created position, she will be responsible for the growth and development of SU2C’s fundraising strategy, focusing on major gifts, corporate philanthropy, digital engagement, and innovation.
Stand Up To Cancer and Johnson & Johnson announced a collaboration aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.
